Dovato - (Eq 50 mg/300 mg; Tablet, Oral)

Generic Name	Dolutegravir Sodium and Lamivudine	Innovator	VIIV Healthcare
Dosage	Eq 50 mg/300 mg; Tablet, Oral	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	Less Than 5
Final Approvals	None	Generic Launches	None
Indication	Dovato is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*****	*** \ *********	*** *, ****	*******	********* ********	***** *** **** (***** ******)

Chronology Of Events